{"disease":{"id":"biliary-cancer","name":"biliary cancer"},"drugs":{"marketed":[{"drug_id":"pemigatinib","indication_name":"Biliary tract cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pemazyre","generic_name":"PEMIGATINIB","company_name":"Incyte Corp","drug_phase":"marketed","molecular_target":"Fibroblast growth factor receptor 1","drug_class":"Kinase Inhibitor [EPC]","quality_score":70,"revenue":"200","mechanism":"Pemazyre blocks the activity of the FGFR1 protein, which is involved in the growth and spread of cancer cells."},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic biliary tract cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of biliary tract cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"zanidatamab","indication_name":"biliary tract cancer (BTC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ziihera","generic_name":"ZANIDATAMAB","company_name":"Jazz Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"Bispecific HER2-directed Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":"Zanidatamab works by binding to two different parts of the HER2 protein, blocking its growth-promoting signals and slowing tumor growth."},{"drug_id":"zanidatamab","indication_name":"biliary tract cancer (BTC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ziihera","generic_name":"ZANIDATAMAB","company_name":"Jazz Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"Bispecific HER2-directed Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":"Zanidatamab works by binding to two different parts of the HER2 protein, blocking its growth-promoting signals and slowing tumor growth."},{"drug_id":"ivosidenib","indication_name":"Biliary tract cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tibsovo","generic_name":"IVOSIDENIB","company_name":"Servier","drug_phase":"marketed","molecular_target":"mutant IDH1","drug_class":"Isocitrate Dehydrogenase 1 Inhibitor [EPC]","quality_score":70,"revenue":null,"mechanism":"Ivosidenib inhibits mutant IDH1, reducing 2-HG levels and promoting myeloid differentiation in AML."}],"pipeline":[],"offLabel":[],"totalMarketed":6,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04731220","title":"A Questionnaire Survey for Biliary Tract Cancers","phase":"","overall_status":"UNKNOWN","enrollment_count":12000,"lead_sponsor_name":"Kyungpook National University Chilgok Hospital","has_results":false},{"nct_id":"NCT07524114","title":"Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception (SHERLOCK)","phase":"","overall_status":"RECRUITING","enrollment_count":7000,"lead_sponsor_name":"University Health Network, Toronto","has_results":false},{"nct_id":"NCT06276153","title":"Construction of Multicenter Retrospective Registry Cohort Database for Gallbladder Cancer","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":5000,"lead_sponsor_name":"RenJi Hospital","has_results":false},{"nct_id":"NCT06252753","title":"Observational Study Protocol: LIVER-R","phase":"","overall_status":"RECRUITING","enrollment_count":4490,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT00339560","title":"A Population-Based Case-Control Study of Biliary Tract Cancers in Shanghai, China","phase":"","overall_status":"COMPLETED","enrollment_count":2624,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05334069","title":"Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Alliance for Clinical Trials in Oncology","has_results":false},{"nct_id":"NCT02628067","title":"Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1609,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT06139042","title":"Early-stage Detection of LIver, Biliary TRAct and PancReatic Cancers","phase":"","overall_status":"RECRUITING","enrollment_count":1608,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT04935853","title":"Prognostic and Predictive Markers of Response to Treatment in Patients With Bile Duct Cancer: ACABi PRONOBIL Study","phase":"","overall_status":"RECRUITING","enrollment_count":1350,"lead_sponsor_name":"GERCOR - Multidisciplinary Oncology Cooperative Group","has_results":false},{"nct_id":"NCT07221253","title":"A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1100,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04637048","title":"Observational Study on Patients With Hepatobiliary Tumors","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"Gang Chen, MD","has_results":false},{"nct_id":"NCT05786482","title":"Evidence Based Mental Wellness Programming Online for Adults Across Chronic Physical Conditions","phase":"NA","overall_status":"COMPLETED","enrollment_count":825,"lead_sponsor_name":"University of Alberta","has_results":false},{"nct_id":"NCT04163900","title":"Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":773,"lead_sponsor_name":"NuCana plc","has_results":true},{"nct_id":"NCT06109779","title":"Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":757,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT03475953","title":"A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":747,"lead_sponsor_name":"Institut Bergonié","has_results":false},{"nct_id":"NCT07101874","title":"A Study to Evaluate the Association of Biliary Complications and Treatment Duration in Unresectable BTC Patients","phase":"","overall_status":"COMPLETED","enrollment_count":729,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04068168","title":"Open Label, Multicenter, Real World Practice of Durvalumab (Imfinzi PMS)","phase":"","overall_status":"COMPLETED","enrollment_count":712,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04644068","title":"Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":702,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT02091141","title":"My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":673,"lead_sponsor_name":"Genentech, Inc.","has_results":true},{"nct_id":"NCT04385147","title":"Advanced Endoscopy During COVID-19","phase":"","overall_status":"COMPLETED","enrollment_count":670,"lead_sponsor_name":"Al-Azhar University","has_results":false},{"nct_id":"NCT06467357","title":"Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":620,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT03797326","title":"Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":611,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT06975917","title":"Adjuvant Chemotherapy Regimens in Resected Biliary Tract Cancers (TOG/GI-SAFRADJU-2501)","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":600,"lead_sponsor_name":"Ankara University","has_results":false},{"nct_id":"NCT05261113","title":"CE-IOUS Impact on Surgical Strategy of Liver Tumours and Liver Metastases","phase":"","overall_status":"COMPLETED","enrollment_count":500,"lead_sponsor_name":"University of Regensburg","has_results":false},{"nct_id":"NCT04158414","title":"Applying PET/MR in Oncology - a Prospective Project","phase":"NA","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Tel-Aviv Sourasky Medical Center","has_results":false},{"nct_id":"NCT05184400","title":"Identification of New Biomarkers for Patients With Cholangiocarcinoma and Gallbladder Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Herlev and Gentofte Hospital","has_results":false},{"nct_id":"NCT05896956","title":"The Construction of Clinical Database and Multiomics Biobank Based on a Multicentral Prospective Cohort of Benign and Malignant Biliary Tract Diseases","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":500,"lead_sponsor_name":"RenJi Hospital","has_results":false},{"nct_id":"NCT05667350","title":"AssesSment of Early-deteCtion basEd oN liquiD Biopsy in Biliary Tract Cancer (ASCEND-BTC)","phase":"","overall_status":"UNKNOWN","enrollment_count":492,"lead_sponsor_name":"Eastern Hepatobiliary Surgery Hospital","has_results":false},{"nct_id":"NCT04401709","title":"Gemcitabine+ Capecitabine Vs Capecitabine in Curatively Resected Biliary Tract Cancer","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":490,"lead_sponsor_name":"Samsung Medical Center","has_results":false},{"nct_id":"NCT04482309","title":"A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":477,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT05123482","title":"A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":460,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT05489211","title":"Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":454,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04445532","title":"Hepatobiliary Tumors Tissue Samples Acquisition","phase":"","overall_status":"UNKNOWN","enrollment_count":450,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT03222258","title":"Prospective Cohort Study Depending on the Use of Palliative Care for Advanced Stage of Cancer Patients","phase":"","overall_status":"COMPLETED","enrollment_count":444,"lead_sponsor_name":"Seoul National University Hospital","has_results":false},{"nct_id":"NCT05517811","title":"Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection","phase":"","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"University of Colorado, Denver","has_results":false},{"nct_id":"NCT04809142","title":"A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule as Second-line Treatment in Subjects With Advanced Biliary Cancer","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":392,"lead_sponsor_name":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","has_results":false},{"nct_id":"NCT04907643","title":"Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes","phase":"NA","overall_status":"RECRUITING","enrollment_count":360,"lead_sponsor_name":"Cedars-Sinai Medical Center","has_results":false},{"nct_id":"NCT06360354","title":"A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":350,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT06849193","title":"Dynamic Prediction Model for Patients with Unresectable Biliary Malignancies Receiving Systemic Chemotherapy Combined with Immunotherapy: a Multicenter, Observational Study","phase":"","overall_status":"RECRUITING","enrollment_count":332,"lead_sponsor_name":"Zhongda Hospital","has_results":false},{"nct_id":"NCT04066491","title":"Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC","phase":"PHASE2, PHASE3","overall_status":"TERMINATED","enrollment_count":309,"lead_sponsor_name":"EMD Serono Research & Development Institute, Inc.","has_results":true},{"nct_id":"NCT06101277","title":"Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)","phase":"NA","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"University of California, Davis","has_results":false},{"nct_id":"NCT07282262","title":"An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT07454486","title":"TRACE-BTC. Relation of Biomarkers and Patients Reported Quality of Life to Outcomes in Patients With Biliary Tract Cancer: a Real- World Cohort","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":300,"lead_sponsor_name":"Aarhus University Hospital","has_results":false},{"nct_id":"NCT05775159","title":"Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":294,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT01589328","title":"Effect of Early Management on PAin and DEpression in Patients With PancreatoBiliary Cancer, EPADE-PB","phase":"NA","overall_status":"COMPLETED","enrollment_count":288,"lead_sponsor_name":"National Cancer Center, Korea","has_results":false},{"nct_id":"NCT06282575","title":"Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":286,"lead_sponsor_name":"Jazz Pharmaceuticals","has_results":false},{"nct_id":"NCT06293898","title":"Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":280,"lead_sponsor_name":"SystImmune Inc.","has_results":false},{"nct_id":"NCT02374255","title":"Improving Goals of Care Discussion in Advanced Cancer Patients","phase":"NA","overall_status":"COMPLETED","enrollment_count":265,"lead_sponsor_name":"Icahn School of Medicine at Mount Sinai","has_results":true},{"nct_id":"NCT07064447","title":"Spanish Registry of Direct Cholangiopancreatoscopy by Single Operator","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":260,"lead_sponsor_name":"Germans Trias i Pujol Hospital","has_results":false},{"nct_id":"NCT06909188","title":"The Study of Association of Helicobacter Infections in Biliary Tract Cancers","phase":"","overall_status":"RECRUITING","enrollment_count":250,"lead_sponsor_name":"Institute of Liver and Biliary Sciences, India","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}